---
document_datetime: 2025-12-02 06:49:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/refacto-af.html
document_name: refacto-af.html
version: success
processing_time: 0.1186425
conversion_datetime: 2025-12-28 13:27:36.89696
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# ReFacto AF

[RSS](/en/individual-human-medicine.xml/65562)

##### Authorised

This medicine is authorised for use in the European Union

moroctocog alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on ReFacto AF](#news-on)
- [More information on ReFacto AF](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for ReFacto AF. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for ReFacto AF.

Expand section

Collapse section

## What is ReFacto AF?

ReFacto AF is a powder and solvent used to make up a solution for injection. ReFacto AF contains the active substance moroctocog alfa. It is available as vials or pre-filled syringes.

## What is ReFacto AF used for?

ReFacto AF is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder). ReFacto AF can be used in patients of all ages, including newborns.

The medicine can only be obtained with a prescription.

## How is ReFacto AF used?

ReFacto AF should be started under the supervision of a doctor who has experience in the treatment of haemophilia A.

ReFacto AF is given by injection into a vein over several minutes. The dose and the frequency of treatment depend on whether ReFacto AF is used to treat or prevent bleeding, the seriousness of the condition, the extent and location of the bleeding or the type of surgery, and the patient's bodyweight. Full details on how to calculate the dose are included in the summary of product characteristics (also part of the EPAR).

Patients or their carers can give injections of ReFacto AF, provided that they have been trained appropriately.

## How does ReFacto AF work?

Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems, such as bleeding in the joints, muscles and internal organs. The active substance in ReFacto AF, moroctocog alfa, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.

The human coagulation factor VIII in ReFacto AF is not extracted from human blood but is produced by a method known as 'recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.

## How has ReFacto AF been studied?

ReFacto AF was first authorised as ReFacto in April 1999, for use in previously treated and untreated patients with haemophilia A, based on the results of three main studies. In February 2009, a number of changes to the way ReFacto is made were introduced. These included removal of the use of a protein called albumin, which is produced from human blood, from the manufacturing process. The name of the medicine was also changed from ReFacto to ReFacto AF.

Following these changes, the company carried out a study to show that ReFacto and ReFacto AF were treated by the body in the same way. It also carried out two main studies looking at the effectiveness of ReFacto AF: the first looked at the prevention and treatment of bleeding episodes in 94 previously treated patients and the second looked at the prevention of bleeding in 22 patients having surgery.

## What benefit has ReFacto AF shown during the studies?

The studies showed that ReFacto AF was as safe and effective as ReFacto in preventing and treating bleeding episodes in patients with haemophilia A.

## What is the risk associated with ReFacto AF?

The most common side effects with ReFacto AF (seen in more than 1 patient in 10) are headache, cough, pain in the joints and fever. Patients may also develop antibodies against factor VIII medicines such as Refacto AF. These are known as inhibitors as they can prevent the medicine from working effectively, which may result in a loss of bleeding control. Uncommonly, patients may also develop allergic reactions. For the full list of all side effects reported with ReFacto AF, see the package leaflet.

ReFacto AF must not be used in people who are hypersensitive (allergic) to human coagulation factor VIII, to any of the other ingredients or to hamster proteins.

## Why has ReFacto AF been approved?

The CHMP noted that ReFacto AF was comparable to ReFacto, the original form of the medicine. Therefore, the Committee decided that the benefits of ReFacto AF are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe use of ReFacto AF?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Refacto AF have been included in the summary of product characteristics and the package leaflet.

## Other information about ReFacto AF

The European Commission granted a marketing authorisation valid throughout the European Union for ReFacto AF on 13 April 1999.

For more information about treatment with ReFacto AF, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

ReFacto AF : EPAR - Summary for the public

English (EN) (78.12 KB - PDF)

**First published:** 05/05/2009

**Last updated:** 29/09/2016

[View](/en/documents/overview/refacto-af-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-877)

български (BG) (103 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/bg/documents/overview/refacto-af-epar-summary-public_bg.pdf)

español (ES) (76.73 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/es/documents/overview/refacto-af-epar-summary-public_es.pdf)

čeština (CS) (100.54 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/cs/documents/overview/refacto-af-epar-summary-public_cs.pdf)

dansk (DA) (76.21 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/da/documents/overview/refacto-af-epar-summary-public_da.pdf)

Deutsch (DE) (78.55 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/de/documents/overview/refacto-af-epar-summary-public_de.pdf)

eesti keel (ET) (75.21 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/et/documents/overview/refacto-af-epar-summary-public_et.pdf)

ελληνικά (EL) (104.89 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/el/documents/overview/refacto-af-epar-summary-public_el.pdf)

français (FR) (77.73 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/fr/documents/overview/refacto-af-epar-summary-public_fr.pdf)

hrvatski (HR) (96.27 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/hr/documents/overview/refacto-af-epar-summary-public_hr.pdf)

italiano (IT) (75.96 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/it/documents/overview/refacto-af-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.84 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/lv/documents/overview/refacto-af-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (99.77 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/lt/documents/overview/refacto-af-epar-summary-public_lt.pdf)

magyar (HU) (96.79 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/hu/documents/overview/refacto-af-epar-summary-public_hu.pdf)

Malti (MT) (102.21 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/mt/documents/overview/refacto-af-epar-summary-public_mt.pdf)

Nederlands (NL) (76.67 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/nl/documents/overview/refacto-af-epar-summary-public_nl.pdf)

polski (PL) (101.87 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/pl/documents/overview/refacto-af-epar-summary-public_pl.pdf)

português (PT) (76.86 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/pt/documents/overview/refacto-af-epar-summary-public_pt.pdf)

română (RO) (97.83 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/ro/documents/overview/refacto-af-epar-summary-public_ro.pdf)

slovenčina (SK) (100.81 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/sk/documents/overview/refacto-af-epar-summary-public_sk.pdf)

slovenščina (SL) (95.69 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/sl/documents/overview/refacto-af-epar-summary-public_sl.pdf)

Suomi (FI) (75.79 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/fi/documents/overview/refacto-af-epar-summary-public_fi.pdf)

svenska (SV) (76.47 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

29/09/2016

[View](/sv/documents/overview/refacto-af-epar-summary-public_sv.pdf)

ReFacto AF : EPAR - Risk-management-plan summary

English (EN) (1.17 MB - PDF)

**First published:** 13/05/2020

[View](/en/documents/rmp-summary/refacto-af-epar-risk-management-plan-summary_en.pdf)

## Product information

ReFacto AF : EPAR - Product Information

English (EN) (816.22 KB - PDF)

**First published:** 22/07/2009

**Last updated:** 05/03/2025

[View](/en/documents/product-information/refacto-af-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-913)

български (BG) (1.04 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/bg/documents/product-information/refacto-af-epar-product-information_bg.pdf)

español (ES) (995.68 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/es/documents/product-information/refacto-af-epar-product-information_es.pdf)

čeština (CS) (876.5 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/cs/documents/product-information/refacto-af-epar-product-information_cs.pdf)

dansk (DA) (983.37 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/da/documents/product-information/refacto-af-epar-product-information_da.pdf)

Deutsch (DE) (906.95 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/de/documents/product-information/refacto-af-epar-product-information_de.pdf)

eesti keel (ET) (993.46 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/et/documents/product-information/refacto-af-epar-product-information_et.pdf)

ελληνικά (EL) (1.03 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/el/documents/product-information/refacto-af-epar-product-information_el.pdf)

français (FR) (1008.13 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/fr/documents/product-information/refacto-af-epar-product-information_fr.pdf)

hrvatski (HR) (1015.56 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/hr/documents/product-information/refacto-af-epar-product-information_hr.pdf)

íslenska (IS) (1009.06 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/is/documents/product-information/refacto-af-epar-product-information_is.pdf)

italiano (IT) (1.01 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/it/documents/product-information/refacto-af-epar-product-information_it.pdf)

latviešu valoda (LV) (1011.22 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/lv/documents/product-information/refacto-af-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.01 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/lt/documents/product-information/refacto-af-epar-product-information_lt.pdf)

magyar (HU) (1003.01 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/hu/documents/product-information/refacto-af-epar-product-information_hu.pdf)

Malti (MT) (1.06 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/mt/documents/product-information/refacto-af-epar-product-information_mt.pdf)

Nederlands (NL) (1 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/nl/documents/product-information/refacto-af-epar-product-information_nl.pdf)

norsk (NO) (1.02 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/no/documents/product-information/refacto-af-epar-product-information_no.pdf)

polski (PL) (936.49 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/pl/documents/product-information/refacto-af-epar-product-information_pl.pdf)

português (PT) (985.26 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/pt/documents/product-information/refacto-af-epar-product-information_pt.pdf)

română (RO) (1002.07 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/ro/documents/product-information/refacto-af-epar-product-information_ro.pdf)

slovenčina (SK) (1010.62 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/sk/documents/product-information/refacto-af-epar-product-information_sk.pdf)

slovenščina (SL) (1.19 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/sl/documents/product-information/refacto-af-epar-product-information_sl.pdf)

Suomi (FI) (1.4 MB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/fi/documents/product-information/refacto-af-epar-product-information_fi.pdf)

svenska (SV) (982.77 KB - PDF)

**First published:**

22/07/2009

**Last updated:**

05/03/2025

[View](/sv/documents/product-information/refacto-af-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000255442 03/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

ReFacto AF : EPAR - All Authorised presentations

English (EN) (31.28 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 19/11/2012

[View](/en/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-647)

български (BG) (67.66 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/bg/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.06 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/es/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.95 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/cs/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.27 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/da/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (30.78 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/de/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.51 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/et/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (68.34 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/el/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_el.pdf)

français (FR) (35.48 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/fr/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (37.27 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/hr/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (29.4 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/is/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_is.pdf)

italiano (IT) (31.45 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/it/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (57.27 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/lv/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.31 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/lt/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.54 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/hu/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.41 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/mt/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.41 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/nl/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (31.95 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/no/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_no.pdf)

polski (PL) (60.93 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/pl/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.1 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/pt/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.94 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/ro/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.75 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/sk/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (39.63 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/sl/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.2 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/fi/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.81 KB - PDF)

**First published:**

19/03/2009

**Last updated:**

19/11/2012

[View](/sv/documents/all-authorised-presentations/refacto-af-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine ReFacto AF Active substance moroctocog alfa International non-proprietary name (INN) or common name moroctocog alfa Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02BD02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).

ReFacto AF is appropriate for use in adults and children of all ages, including newborns.

ReFacto AF does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.

## Authorisation details

EMA product number EMEA/H/C/000232 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Marketing authorisation issued 13/04/1999 Revision 41

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

ReFacto AF : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.95 KB - PDF)

**First published:** 22/07/2009

**Last updated:** 05/03/2025

[View](/en/documents/procedural-steps-after/refacto-af-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

ReFacto AF-H-C-232-P46-146 : EPAR - Assessment Report

Adopted

Reference Number: EMA/203131/2019

English (EN) (1.15 MB - PDF)

**First published:** 14/08/2019

[View](/en/documents/variation-report/refacto-af-h-c-232-p46-146-epar-assessment-report_en.pdf)

ReFacto AF-H-C-0232-A31-0134 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/763977/2017

English (EN) (220.01 KB - PDF)

**First published:** 05/12/2017

**Last updated:** 05/12/2017

[View](/en/documents/variation-report/refacto-af-h-c-0232-a31-0134-epar-assessment-report-article-31_en.pdf)

ReFacto AF-H-C-232-P46-142 : EPAR - Assessment Report

Adopted

Reference Number: EMA/800795/2016

English (EN) (296.21 KB - PDF)

**First published:** 30/11/2016

**Last updated:** 30/11/2016

[View](/en/documents/variation-report/refacto-af-h-c-232-p46-142-epar-assessment-report_en.pdf)

ReFacto AF-H-C-232-P46-FUM-0132 : EPAR - Assessment Report

Adopted

Reference Number: EMA/750455/2012

English (EN) (107.66 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 29/11/2012

[View](/en/documents/variation-report/refacto-af-h-c-232-p46-fum-0132-epar-assessment-report_en.pdf)

ReFacto AF-H-C-232-P46-FUM-0136 : EPAR - Assessment Report

Adopted

Reference Number: EMA/750456/2012

English (EN) (140.22 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 29/11/2012

[View](/en/documents/variation-report/refacto-af-h-c-232-p46-fum-0136-epar-assessment-report_en.pdf)

Refacto AF-H-C-232-II-0059-0068 : EPAR - Assessment Report - Variation

Reference Number: EMEA/55167/2009

English (EN) (723.89 KB - PDF)

**First published:** 19/03/2009

**Last updated:** 19/03/2009

[View](/en/documents/variation-report/refacto-af-h-c-232-ii-0059-0068-epar-assessment-report-variation_en.pdf)

ReFacto AF : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (105.57 KB - PDF)

**First published:** 08/09/2006

**Last updated:** 08/09/2006

[View](/en/documents/steps-after-cutoff/refacto-af-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

ReFacto AF : EPAR - Procedural steps taken before authorisation

English (EN) (86.54 KB - PDF)

**First published:** 08/09/2006

**Last updated:** 08/09/2006

[View](/en/documents/procedural-steps/refacto-af-epar-procedural-steps-taken-authorisation_en.pdf)

ReFacto AF : EPAR - Scientific Discussion

English (EN) (176.14 KB - PDF)

**First published:** 08/09/2006

**Last updated:** 08/09/2006

[View](/en/documents/scientific-discussion/refacto-af-epar-scientific-discussion_en.pdf)

#### News on ReFacto AF

[Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes](/en/news/factor-viii-medicines-no-clear-consistent-evidence-difference-risk-inhibitor-development-between-classes) 15/09/2017

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 May 2016](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-may-2016) 13/05/2016

#### More information on ReFacto AF

- [Factor VIII - referral](/en/medicines/human/referrals/factor-viii)
- [A POST AUTHORIZATION SAFETY SURVEILLANCE REGISTRY IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A IN USUAL CARE SETTINGS - post-authorisation study](https://catalogues.ema.europa.eu/study/6917)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/03/2025

## Share this page

[Back to top](#main-content)